New infographic highlights state of drug approvals in 2013

NDA Group has launched a new infographic that highlights the state of drug approvals in Europe and the US.

The new infographic draws on official data released from EMA and FDA, and focuses in on the following key findings:

• The differences in drug approvals between the USA (FDA) and the EU (EMA)
• Breaks-out results by therapeutic areas
• Compares the time taken to get drugs approved, and shows the significant difference in drug approval times between the EU and the US
• Shows the percentage of top pharma vs the rest of the industry in gaining drug approvals
• Breaks-out those that received ‘Special Status’ in the EU and the US.

Drug approval was 174 days faster in the US than in the EU.

There were a total of 84 drug approvals: 60 in the EU, 40 in the US, 16 of which were in both. Of the 84 drug approvals:

• 27 were biologics
• 53% were for top pharma companies
• 15 were classified as orphan drugs
• 19 received special status for approval
• 10 were for treating central nervous system conditions.